Approach: Engineered and targeted cytokines to treat autoimmune diseases
Strategic Area: Immunotherapies
T1D Funding Impact: Bringing T1D focus and experience to a multi-indication drug
Location: France, Ile-de-France, Paris
Investors 5
| Date | Name | Website |
| 06.02.2022 | Takeda Ven... | takeda.com |
| 02.08.2022 | T1D Fund | t1dfund.or... |
| - | Fund+ | fundplus.b... |
| - | Bioqube Ve... | bioqubeven... |
| 18.04.2022 | Life Scien... | lspvc.com |
Mentions in press and media 5
| Date | Title | Description | Source |
| 10.04.2024 | EGLE announces $320,000 grant opportunity for community sola... | The Energy Unit of the Michigan Department of Environment, Great Lakes, and Energy (EGLE) is offerin... | einpresswi... |
| 25.10.2021 | Democrats look to Billionaire tax on unrealized capital gain... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 22.10.2021 | Egle Therapeutics Raises €40M in Series A Funding | Egle Therapeutics, a Paris, France-based biotechnology company that focuses on developing First-In-C... | finsmes.co... |
| 22.10.2021 | Egle Therapeutics raises 40 million € Series A to develop Fi... | Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Clas... | fundplus.b... |
| - | Egle Therapeutics raises 40 million € Series A to develop Fi... | LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate | bioqubeven... |